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ABSTRACT
DNA repair pathways present in all cells serve to preserve genome stability, but 
in cancer cells they also act reduce the efficacy of chemotherapy. The endonuclease 
ERCC1-XPF has an important role in the repair of DNA damage caused by a variety 
of chemotherapeutic agents and there has been intense interest in the use of ERCC1 
as a predictive marker of therapeutic response in non-small cell lung carcinoma, 
squamous cell carcinoma and ovarian cancer. We have previously validated ERCC1 
as a therapeutic target in melanoma, but all small molecule ERCC1-XPF inhibitors 
reported to date have lacked sufficient potency and specificity for clinical use. In an 
alternative approach to prevent the repair activity of ERCC1-XPF, we investigated the 
mechanism of ERCC1 ubiquitination and found that the key region was the C-terminal 
(HhH)2 domain which heterodimerizes with XPF. This ERCC1 region was modified by 
non-conventional lysine-independent, but proteasome-dependent polyubiquitination, 
involving Lys33 of ubiquitin and a linear ubiquitin chain. XPF was not polyubiquitinated 
and its expression was dependent on presence of ERCC1, but not vice versa. To our 
surprise we found that ERCC1 can also homodimerize through its C-terminal (HhH)2 
domain. We exploited the ability of a peptide containing this C-terminal domain to 
destabilise both endogenous ERCC1 and XPF in human melanoma cells and fibroblasts, 
resulting in reductions of up to 85% in nucleotide excision repair and near two-fold 
increased sensitivity to DNA damaging agents. We suggest that the ERCC1 (HhH)2 
domain could be used in an alternative strategy to treat cancer.
INTRODUCTION
As a key endonuclease in a major DNA repair 
pathway, the role of ERCC1-XPF in the development of 
ageing [1, 2], neurodegenerative disease [3] and especially 
in multiple forms of cancer (reviewed in [4]) has been 
widely investigated. Despite the success of new targeted 
cancer therapies, DNA-damaging chemotherapeutics 
remain the current mainstay of treatments for the majority 
of common cancers. DNA repair pathways present in all 
cells serve to preserve genome stability, but in cancer 
cells they also act to reduce the efficacy of chemotherapy. 
ERCC1-XPF has an important role in the repair of DNA 
damage caused by a variety of chemotherapeutic agents. 
It is essential for the nucleotide excision repair (NER) 
pathway that removes helix-distorting lesions caused by 
UV irradiation, bulky alkylating agents and intrastrand 
cross-linkers. It also has an important role in removal 
of the particularly toxic, and so therapeutically very 
effective, interstrand crosslinks (ICLs, reviewed in [4]) 
Since the most commonly used cancer chemotherapeutics, 
platinating agents such as cisplatin and carboplatin, cause 
all three types of lesion, there has been intense interest in 
the use of ERCC1 as a predictive marker of therapeutic 
response to these agents. 
High ERCC1 expression at the mRNA or protein 
level has been linked in many studies with poor response 
to chemotherapy: non-small cell lung carcinoma [5–8]; 
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squamous cell carcinoma [9, 10]; and ovarian cancer [11]. 
However, this correlation was not universal [12–14] 
and lack of specificity of many of the antibodies used 
for immunohistochemical detection of ERCC1 has been 
documented [15]. Lack of correlation between ERCC1 
mRNA and protein levels in ovarian cancers has also been 
reported [11], suggesting that there is not a simple direct 
relationship between ERCC1 mRNA levels and DNA 
repair capacity. 
Additional complications in the use of ERCC1-
XPF as a predictive marker of response are the need to 
carefully regulate the endonuclease activity of ERCC1-
XPF to prevent activity on non-damaged DNA and the 
requirement to function as a heterodimer. ERCC1 is 
principally responsible for recruitment to repair foci 
and XPF provides the endonuclease activity (reviewed 
in [4]). Previous observations indicated that ERCC1 
and XPF molecules outside ERCC1-XPF heterodimers 
are rapidly degraded [16]. Xeroderma pigmentosum 
patients belonging to the XPF complementation group 
have reduced cellular levels of both XPF and ERCC1 
and, conversely, ERCC1-deficient cells show low levels 
of XPF, implying that formation of the heterodimeric 
complex stabilises both proteins in vivo [17, 18]. The 
key protein-protein interaction between ERCC1 and 
XPF is dimerization of the hydrophobic C-terminal 
regions through their double helix-hairpin-helix (HhH2) 
domains [19, 20]. Without heterodimerization it was 
conventionally thought neither protein was stable and 
that, following exposure of their hydrophobic interaction 
regions, each was rapidly degraded [20, 21]. However, 
more recent siRNA experiments have indicated that, while 
XPF protein levels were decreased when ERCC1 was 
knocked down, the converse was not true [22].
We have previously validated ERCC1 as a 
therapeutic target by showing that a genetically engineered 
ERCC1-deficient mouse model of melanoma was uniquely 
sensitive to the chemotherapeutic cisplatin [23]. Inhibitors 
of the ERCC1/XPA interaction with activity against 
colorectal and lung cancer cell lines have been reported 
[24, 25] and an in silico drug screen identified compounds 
that can disrupt ERCC1-XPF complex stability in cell 
lysates [26]. However, despite the availability of structural 
information and much endeavour, these studies and our 
own efforts [27–29] had been unable to identify ERCC1-
XPF inhibitors of sufficient potency and specificity in 
preclinical models to cause the major reductions in NER 
activity and increased sensitivity to DNA damaging agents 
needed to justify further development.
Instead we chose to investigate the relationship 
between ERCC1-XPF and the response to cisplatin in 
melanoma -a cancer notoriously resistant to chemotherapy. 
A study of six human melanoma cell lines (Yang and 
Melton, unpublished) showed that, although mRNA 
levels of both ERCC1 and XPF were increased by 
cisplatin treatment as we had reported previously [30], the 
correlation with ERCC1 and XPF protein levels varied 
between the cell lines, raising the possibility that post-
translational modification may also play an important role 
in the regulation of ERCC1-XPF repair activity. Since 
ubiquitin modification is involved in the regulation of 
both DNA repair activity and DNA repair protein levels 
(reviewed in [31]), we chose to investigate the detailed 
mechanism of ERCC1 ubiquitination. During the course 
of this investigation reported here we also discovered that, 
contrary to conventional understanding, ERCC1 can also 
form homodimers in human cells. We further exploited a 
peptide containing this dimerization domain to destabilise 
both endogenous ERCC1 and XPF, resulting in major 
reductions in nucleotide excision repair and increased 
sensitivity to DNA damaging agents in melanoma 
cells. These results suggest that this approach could be 
developed into a viable therapeutic alternative to small 
molecule inhibitors.
RESULTS
The proteasome system is involved in the 
stability of ERCC1 but not XPF
To investigate the possibility that ubiquitin 
modification is involved in the regulation of ERCC1 and 
XPF, we used western blotting to assess the response of both 
proteins from two human melanoma cell lines, A375 (from a 
metastatic melanoma) and C32 (from a primary melanoma), 
to proteasome inhibitor MG132 and translation inhibitor 
cycloheximide (Supplementary Figure 1). In both cell lines 
exposure to MG132 caused a time-dependent increase in 
levels of ERCC1, but not of XPF. In cycloheximide-exposed 
samples, ERCC1 showed a time-dependent decrease, while 
XPF again showed no clear change. We concluded that 
the ubiquitin proteasome system may be involved in the 
stability of ERCC1, but not XPF.
ERCC1 is modified by polyubiquitination 
involving Lys 33 of ubiquitin and by linear 
polyubiquitination
To investigate ubiquitination of ERCC1, 
ubiquitination assays were performed following 
overexpression in A375 melanoma cells of non-tagged 
wild-type human ERCC1 and a series of 6xHis-tagged 
wild-type human ubiquitin constructs, with or without 
exposure to MG132 (Figure 1). 10% of cells from each 
sample were lysed as the input sample, the remainder 
were extracted and purified on Ni-NTA-agarose beads 
as the IP sample. Overexpression of ERCC1 was clearly 
visible in the input sample blot, with a further increase 
following exposure to MG132, but no clear change in 
levels of endogenous XPF was seen (Figure 1A). In the 
IP sample blot, compared with the non-transfected control 
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Figure 1: ERCC1 is modified by ubiquitination involving both ubiquitin Lys 33 and linear polyubiquitination. (A) 
6xHis-tagged wild-type (WT) human ubiquitin and non-tagged wild-type human ERCC1 were co-transfected into A375 cells in duplicate 
60 mm dishes, while non-transfected, ubiquitin (WT) transfected-only and ERCC1 (WT) transfected-only duplicate dishes served as 
controls. After 24 h, one dish from each pair was exposed to MG132 (25 µΜ) for 5 h and the in vivo ubiquitination assay was then performed. 
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and 6xHis-tagged ubiquitin transfected-only control, 
the 6xHis-tagged ubiquitin and non-tagged ERCC1 co-
transfected samples showed multiple bands, indicating 
polyubiquitination or multiple monoubiquitination of 
ERCC1. The co-transfected MG132-exposed sample 
showed a stronger ubiquitin ladder. Current understanding 
of proteasome-dependent protein degradation is that the 
substrate is first polyubiquitinated and then degraded by 
the 26S proteasome, containing a 20S catalytic unit and 
two 19S regulatory units, or alternatively substrate may 
be degraded in a ubiquitin-independent manner by a 
proteasome containing the 20S catalytic unit and different 
regulator units, such as 11S [32, 33]. So we interpret 
our result to indicate that ERCC1 is more likely to be 
polyubiquitinated. By rerunning IP and input samples 
together on the same gel, we showed that the bottom 
rung of the ubiquitinated ERCC1 ladder comigrated 
with the 38 kD ERCC1 input monomer (Supplementary 
Figure 2A). Interpretation of the number of ubiquitins (an 
8.5 kD monomer) added to ERCC1 in the co-transfected 
samples was complicated by the result in the two non-
tagged ERCC1 transfected-only control lanes. In addition 
to the cross-reacting band at 70 kD present in all IP 
samples, these lanes contained two additional bands also 
present in the co-transfected samples. The smaller band 
at 38 kD comigrated with non-modified ERCC1, with the 
size of the larger band consistent with ERCC1 modified 
by one ubiquitin. These bands may be present as a result 
of some non-specific binding of overexpressed ERCC1 to 
the beads. For the co-transfected panel, the sizes of the 
other three bands are consistent with ERCC1 modified 
by two, three and four ubiquitins. Endogenous XPF was 
unaffected by any of these treatments.
We next investigated whether either of the two most 
common ubiquitin linkages regulating protein stability, 
Lys48 (proteasome-mediated proteolysis, [34]) and Lys63 
(lysosome-mediated proteolysis, [35]) were involved in 
ERCC1 ubiquitination (Figure 1B). Non-tagged ERCC1 
was co-transfected with 6xHis-tagged wild-type human 
ubiquitin, plant ubiquitin 7R where all 7 lysines were 
mutated to arginine (initially only an Arabidopsis thaliana, 
rather than a human 7R construct was available), human 
ubiquitin K48R (Lys48 mutated to Arg) and ubiquitin 
K63R. Ubiquitin mutants K48R and K63R showed the 
same ubiquitination ladder as the wild type, with increased 
intensity in MG132-exposed samples. As expected, the 
ubiquitination ladder was absent from the plant ubiquitin 
(7R) samples. We conclude that ERCC1 is not regulated 
through Lys48- or Lys63- linked ubiquitination. Therefore, 
the role of additional ubiquitin lysines (K6, K11, K27, 
K29) was investigated in the same way (Figure 1C). All 
mutants showed the identical ubiquitination ladder as the 
wild type. Supplementary Figure 2B shows the entire gel 
run on these IP samples, revealing a weak ubiquitination 
smear, extending above the discrete four-runged 
ubiquitination ladder in all MG132-exposed samples.
The remaining ubiquitin lysine mutant K33R was 
investigated together with ubiquitin combination mutants 
(29K only), (33K only), (48K only) and (63K only), where 
the remaining six lysines in each construct were all mutated 
to arginine. A new human, rather than plant, ubiquitin 
(7R) negative control was also used (Figure 1D). Unlike 
all of the other point mutants, K33R gave a much weaker 
ubiquitination ladder than wild-type ubiquitin. All four 
combination mutants tested gave ubiquitination ladders, 
but only the ubiquitin (33K only) mutant gave a ladder 
Material purified on Ni beads was western blotted for ERCC1. The ubiquitinated ERCC1 ladder, extending to 70 kD is identified, as is the 
position of non-ubiquitinated ERCC1 at 38 kD (unmodified ERCC1 consistently runs at this position although the predicted mol wt of the 
297 amino acid protein is 32.57 kD). *, denotes a cross-reacting band, also at 70 kD, present in all samples. A sample of the input material 
prior to purification was also blotted for ERCC1, XPF and beta-actin. Note the difference between low endogenous ERCC1 expression only 
in the first four lanes of the input blot and high vector-derived plus endogenous ERCC1 expression in the rest of the gel. (B) Non-tagged 
wild-type ERCC1 was transfected alone into A375 cells, or co-transfected with one of four different 6xHis-tagged ubiquitin constructs: 
wild-type human ubiquitin, plant (Arabidopsis thaliana) ubiquitin 7R (where all 7 Lysines were mutated to Arginines), human ubiquitin 
point mutants (K48R) and (K63R). Dishes were then treated and processed as for panel A. Note the lack of ubiquitination ladder with the 
plant ubiquitin (7R) mutant and that ubiquitin (K48R) and (K63R) mutants give the same ubiquitination ladder as wild-type ubiquitin. 
(C) Non-tagged wild-type ERCC1 was co-transfected into A375 cells with a 6xHis-tagged human wild-type, or point mutant ubiquitin 
construct: ubiquitin (K6R), ubiquitin (K11R), ubiquitin (K27R), ubiquitin (K29R). Dishes were then treated and processed as for panel A. 
(D) Non-tagged wild-type ERCC1 was co-transfected into A375 cells with 6xHis-tagged human wild-type, or the human ubiquitin (7R) 
multiple mutant, or point mutant ubiquitin (K33R), or a combination mutant: ubiquitin (K29 only), ubiquitin (K33 only), ubiquitin (K48 
only), ubiquitin (K63 only). Dishes were then treated and processed as for panel A. Note the altered ubiquitination pattern with the (K33R) 
mutant. Note the stronger ubiquitination with ubiquitin (K33 only) after MG132 treatment compared with the other three combination 
mutants. Note also the strong ubiquitination pattern with human ubiquitin (7R), compared to the plant ubiquitin (7R) mutant in panel B. (E) 
To investigate linear polyubiquitination, non-tagged wild-type ERCC1 was co-transfected into A375 cells in duplicate 100 mm dishes with 
6xHis-tagged human wild-type ubiquitin or ubiquitin (7R). After 24 h, one dish from each pair was exposed to MG132 (25 µΜ) for 5 h. 
Non-transfected, ubiquitin (WT) transfected-only and ERCC1 (WT) transfected-only dishes, all exposed to MG132, were used as controls. 
Immunoprecipitation was performed on cell extracts with an antibody specific for linear polyubiquitination and collected with magnetic 
protein A beads. Material eluted from the beads was western blotted for ERCC1. The position of ERCC1 with linear polyubiquitin chains is 
indicated, as is the position of heavy chain immunoglobulin. A sample of the input material prior to immunopurification was also blotted for 
ERCC1 and beta-actin. Note the linear polyubiquitination ERCC1 bands in the co-transfection with wild-type ubiquitin with the stronger 
signal after MG132 exposure, and the weaker signal in the co-transfection with ubiquitin (7R).
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intensity equivalent to wild type. We conclude that K33 of 
ubiquitin has a role in, but is not sufficient for, proteasome 
dependent ubiquitination of ERCC1. Intriguingly, in 
negative control human ubiquitin (7R) samples, which 
were expected to lack a ubiquitin ladder in the same way 
as with the plant ubiquitin (7R) in Figure 1B, the ubiquitin 
ladder was as strong as for wild-type ubiquitin. This could 
be due to linear polyubiquitination involving an N-Met, 
rather than an internal lysine linkage [36]. The failure to 
see this with the plant (7R) mutant could result from an 
altered structure due to the three amino acid differences 
from human ubiquitin.
To investigate if linear polyubiquitination of ERCC1 
occurs, conventional immunoprecipitation with a linear 
polyubiquitin-specific monoclonal antibody and magnetic 
Protein A beads was carried out following co-transfection 
into A375 cells of wild-type non-tagged ERCC1 with 
human ubiquitin wild-type and ubiquitin (7R) (Figure 1E). 
5 mM iodoacetamide was added to all the buffers just 
before use to inhibit deubiquitinase activity. The full 
gel of the input samples (Supplementary Figure 2C) 
shows that a ubiquitination ladder can also be seen from 
overexpressed ERCC1 without immunopurification. In the 
IP panel, compared with the controls, two additional bands 
with sizes corresponding to ERCC1 modified by 3 or 4 
ubiquitins were seen in the co-transfection with ubiquitin 
(WT). Importantly, the larger band was also present, but at 
lower intensity, in the co-transfection with ubiquitin (7R). 
The lower intensity may be because the mutations affect 
the ubiquitin structure, which could influence ubiquitin 
chain structure and the recognition sensitivity of the 
antibody. In both cases, the band was stronger following 
MG132 exposure, suggesting that that the stability 
of ERCC1 is indeed regulated by polyubiquitination 
involving Lys33 of ubiquitin and linear polyubiquitination.
The XPF binding domain of ERCC1 is the key 
domain for proteasome-dependent degradation
We next investigated the key domain(s) on ERCC1 
for ubiquitination-dependent degradation. The domain 
structure of the ERCC1 protein is shown in Figure 2A. 
Since the epitopes for our favoured ERCC1 polyclonal 
antibody (FL297) were not evenly distributed between the 
domains, we made deletion constructs with and without an 
N-terminal Flag tag: ERCC1 (1-297), (1-219), (96-297) 
and (220-297) (Figure 2A). Constructs were co-transfected 
into A375 cells with 6xHis-tagged wild-type ubiquitin 
and the ubiquitination assay was performed. For the 
non-tagged samples (Figure 2B), the full-length ERCC1 
(1-297) panel showed the same ubiquitination ladder, at 
increased intensity following MG132 exposure, as seen 
in Figure 1. The ERCC1 (1-219) input samples showed 
much stronger signals than for ERCC1 (1-297), but with 
no increase after MG132 exposure. In the ERCC1 (1-219) 
IP samples, there was no extensive ubiquitination ladder 
and again there was no effect of MG132 exposure. We 
conclude that ERCC1 (1-219) is not required for ubiquitin-
dependent proteasome degradation. Only weak bands were 
present in the MG132-exposed ERCC1 (96-297) samples 
and no bands were detected for ERCC1 (220-297). This 
could be as a result of the lack of sufficient epitopes for 
detection by the ERCC1 antibody, or increased protein 
degradation.
This uncertainty was resolved when the assay was 
repeated with the Flag-tagged ERCC1 constructs and 
an anti-Flag antibody (Figure 2C). For ERCC1 (1-297)-
Flag and (1-219)-Flag the result with the non-tagged 
constructs was confirmed. As expected, the ERCC1 (96-
297)-Flag and ERCC1 (220-297)-Flag panels showed 
stronger signals than the non-tagged panels. For ERCC1 
(96-297)-Flag, the ERCC1 band in the input samples 
was much weaker than with ERCC1 (1-297)-Flag and 
(1-219)-Flag, with an increase after MG132 exposure. 
Intriguingly, the ubiquitination ladder for the ERCC1 
(96-297)-Flag IP sample was much stronger than for 
ERCC1 (1-297)-Flag and (1-219)-Flag, particularly after 
MG132 exposure. This indicates that the presence of the 
N-terminal (1-95) domain can partially protect ERCC1 
from proteasome degradation. For ERCC1 (220-297)-Flag 
input and IP samples, only the MG132-exposed samples 
showed detectable bands, indicating that expression of this 
domain alone results in rapid degradation by the ubiquitin-
dependent proteasome pathway. 
To exclude the possibility that ERCC1 deletion 
constructs were interacting differently with the ubiquitin-
dependent proteasome degradation pathway due to the 
altered subcellular location of their encoded ERCC1 
proteins, immunofluorescence was carried out for the 
Flag-tagged ERCC1 constructs in A375 cells, together 
with nuclear and cytoplasmic markers (Figure 2D). As 
expected, all ERCC1 proteins were predominantly located 
in nuclei, allowing us to conclude that the key residue(s) 
involved in ubiquitin-dependent proteasome degradation 
are indeed present in the XPF binding domain of ERCC1, 
residues 220-297.
XPF is not ubiquitinated but its stability is 
affected by ERCC1 ubiquitination 
Could the ubiquitin-dependent proteasome 
degradation of overexpressed ERCC1 simply be an 
artefact caused by lack of matching amounts of its XPF 
binding partner? To address this question, we repeated 
the ubiquitination assay on the Flag-tagged ERCC1 
truncations after co-transfecting a Flag-tagged full-
length XPF construct (Figure 2E). The input samples 
and characteristic ubiquitination patterns of full-length 
and truncated ERCC1 proteins were all unaffected by the 
presence of overexpressed XPF. There was no evidence for 
XPF ubiquitination in any samples, indicating that it is not 
itself a substrate for the ubiquitin-dependent proteasome 
Oncotarget6www.impactjournals.com/oncotarget
Figure 2: The XPF binding domain of ERCC1 determines the stability of both ERCC1 and XPF. (A) Schematic of protein 
domains and exon boundaries for full-length (1-297) ERCC1 protein and deletion constructs (1-219), (96-297) and (220-297). Constructs 
were made with and without an N-terminal Flag tag. The predicted sizes (pre.) of non-tagged constructs are shown. Arrows beneath each 
construct indicate the location of epitopes for the ERCC1 polyclonal antibody (FL297). (B) Ubiquitination of ERCC1 deletion constructs. 
6xHis-tagged wild-type ubiquitin was co-transfected into A375 cells in duplicate 60 mm dishes with non-tagged ERCC1 (1-297), (1-219), 
(96-297) and (220-297) for in vivo ubiquitination assay. After 24 h one dish from each pair was exposed to MG132 (25 µΜ) for 5 h. Material 
purified on the Ni beads was western blotted for ERCC1. A sample of the input material prior to purification was also blotted for ERCC1 
and beta-actin. Note the less extensive ubiquitination ladder with lack of an MG132-induced increase in ubiquitination with ERCC1 (1-219) 
compared to the (1-297) construct and the difficulty of detecting the (220-297) and (96-297) constructs. (C) Ubiquitination of Flag-tagged 
ERCC1 deletion constructs. The in vivo ubiquitination assay shown in Panel B was repeated using Flag-tagged ERCC1 constructs and an 
antibody against the Flag tag. Note again the less extensive ubiquitination ladder and lack of an MG132-induced increase in ubiquitination 
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degradation pathway. However, presence of Flag-tagged 
XPF was dependent on overexpression of ERCC1. In both 
IP and input samples the XPF signal was very weak or 
undetectable in the no ERCC1 overexpressed samples, 
the co-transfection with ERCC1 (1-219)-Flag, which is 
without an XPF binding domain, and the co-transfection 
with ERCC1 (220-297)-Flag where the ERCC1 is rapidly 
degraded. Moreover, for XPF co-transfected with ERCC1 
(1-297)-Flag and ERCC1 (96-297)-Flag, XPF was 
reduced in both the MG132-exposed input and IP samples 
whereas full-length ERCC1 or ERCC1 (96-297) was 
accumulated. We conclude that the ubiquitin-dependent 
proteasome degradation of ERCC1 is not due to lack of 
its XPF binding partner. However, XPF is dependent on 
the presence of ERCC1 for its stability and its stability is 
reduced by ubiquitination of ERCC1. 
The C-terminal (HhH)2 XPF binding domain 
of ERCC1 is polyubiquitinated in a non-
conventional lysine-independent manner
We next investigated the ubiquitination site(s) in 
the C-terminal (HhH)2 XPF binding domain of ERCC1 
necessary for proteasome degradation. While serine 
hydroxyl and cysteine thiol groups of the substrate can 
be modified by ubiquitin [37–39], ubiquitin conjugation 
is mostly through an amide isopeptide bond between 
the C-terminus of ubiquitin and a ε-amino group of a 
lysine residue on the target protein [40]. Three of the 
five lysines present, Lys243, Lys281 and Lys295, were 
reported to be modified in a global mass spectrometry 
assay (phosphosite plus, http://www.phosphosite.org/
homeAction.do). The crystal structure of the strong 
interaction between the double helix-hairpin-helix (HhH)2 
domains of ERCC1 and XPF has been determined [20]. 
We found that the ε-amino groups of all five ERCC1 
lysines were exposed in this structure, so having the 
potential to be ubiquitinated (Supplementary Figure 3A). 
Of the five hydrogen bond pairs between ERCC1 and 
XPF (Gly258-Phe894, Arg234-Lys843, Glu261-Ile890, 
Leu289-Ala863 and Phe293-Lys860) all, apart from 
Glu261-Ile890, were linked in hydrogen bond chains with 
ERCC1 lysines (Supplementary Figure 3B and 3C). In 
addition, the ring of ERCC1 Phe293 fits perfectly into a 
hydrophobic cavity formed by the (HhH)2 motif of XPF. 
ERCC1 lacking the last four residues including Lys295 
still binds to XPF, whereas deletion of the next residue, 
Phe293, eliminates XPF binding [16]. Thus, there is the 
potential for ubiquitination of any of these ERCC1 lysines 
to destabilise the binding of ERCC1 to XPF.
Ubiquitination assays were carried out as before 
with ERCC1 constructs where lysines in the XPF binding 
domain of ERCC1, (K226R), (K243R), (K247R), 
(K281R) and (K295R), were individually mutated to 
arginine. Mutants were co-transfected into A375 cells with 
6xHis-tagged wild-type ubiquitin (Figure 3A). Compared 
with the ERCC1 wild-type samples, the ERCC1 input 
protein level and ubiquitination ladder were reduced in 
both ERCC1 (K226R) and ERCC1 (K281R) samples. We 
cannot conclude just from this result that these are key 
lysines for ubiquitination because these mutations might 
affect the ERCC1 structure and so alter the recognition 
by E3 ligase during ERCC1 ubiquitination. To investigate 
further, we repeated the assay with combination mutants 
ERCC1 K(226, 281)R, K(226, 295)R and K(247, 295)R, 
where two lysines were mutated to arginine and ERCC1 
(5R), where all five lysines were mutated (Figure 3B). 
None of the combination mutants prevented ERCC1 
ubiquitination, indeed the ERCC1 K(226, 281)R samples 
showed a stronger ubiquitination ladder than the wild 
type. We conclude that the proteasome-dependent 
degradation of ERCC1 relies on non-conventional 
ubiquitin modification of the XPF binding domain that is 
independent of lysine residues. 
The C-terminal (HhH)2 XPF binding domain 
of ERCC1 is essential for nucleotide excision 
repair but the constituent lysine residues are not 
required
Although none of the lysines in the XPF 
binding domain of ERCC1 were essential for ERCC1 
polyubiquitination, this did not preclude a role in NER 
activity. A transfection-based NER assay originally 
developed for use in ERCC1-proficient A375 cells to 
assess the efficacy of small molecule ERCC1 inhibitors 
[27] was first validated for use with ERCC1 constructs in 
ERCC1-null A375 cells that were generated by CRISPR/
with ERCC1 (1-219) compared to all the other constructs, the particularly strong ubiquitination ladder with the (96-297) construct and the 
reduced levels of non-modified ERCC1 with both (96-297) and (220-297) constructs. (D) Nuclear location of Flag-tagged ERCC1 deletion 
constructs. 1x105 A375 cells growing on coverslips in 6-well plates were transfected with 1 µg of each Flag-tagged ERCC1 truncation. 
24 h later live cells were stained with mitochondria tracker to identify cytoplasm before cells were fixed for immunofluorescence with 
an FITC-conjugated anti-Flag antibody and DAPI staining to identify nuclei. Images in the three individual fluorescence channels and 
an image merge are shown. Note the predominantly nuclear location of proteins encoded by all ERCC1 constructs. (E) Ubiquitination of 
ERCC1 is not influenced by cotransfection of XPF, but XPF depends on ERCC1 for stability. Flag-tagged ERCC1 (1-297), (1-219), and 
(96-297) constructs were co-transfected into A375 cells with 6xHis-tagged ubiquitin and Flag-tagged full-length XPF in duplicate dishes. 
Co-transfections of Flag-tagged ERCC1 (1-297) with 6xHis-tagged ubiquitin and of Flag-tagged XPF and 6xHis-tagged ubiquitin served 
as controls. After 24 h one dish from each pair was exposed to MG132 (25 µΜ) for 5 h and the in vivo ubiquitination assay was performed 
as described. The positions of Flag-tagged ERCC1 truncations and ubiquitinated truncations are indicated on the gels. Note that the amount 
of XPF is dependent on the presence and stability of the ERCC1 (220-297) domain.
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Cas9 genome editing specifically for this purpose. 
ERCC1-null A375 cells were co-transfected in 96-well 
plates with ERCC1 wild-type and deletion mutants 
ERCC1 (1-219), (96-297) and (220-297), together with an 
XPF expression plasmid, a UV-damaged or non-damaged 
GFP plasmid and a transfection control luciferase plasmid. 
GFP fluorescence and luciferase luminescence were 
measured 48 h after transfection. DNA repair activity of 
the deletion mutant ERCC1 (96-297) was equivalent to 
the wild-type ERCC1, but deletion mutants ERCC1 (1-
219) and (220-297) showed no DNA repair activity at all 
(Figure 3C). This assay demonstrated the essential roles 
of the central and XPF binding domains of ERCC1 and so 
validated it to investigate the effect on NER of the ERCC1 
point mutants. 
All five of the single lysine mutants tested, ERCC1 
(K226R), (K243R), (K247R), (K281R), (K295R), and 
ERCC1 (5R), where all five lysines were mutated, showed 
good NER activity compared to the deletion mutants 
ERCC1 (1-219) and (220-297) (Figure 3D). Although all 
except (K243R) showed lower activity than the wild-type 
control, in no case were any of the differences significant 
and we conclude that these lysine residues are not involved 
in the function and stability of ERCC1-XPF. 
Homodimerization of over-expressed ERCC1 
occurs and ERCC1 (220-297) can be used to 
destabilise co-transfected wild-type ERCC1
Our observation, that over-expressed ERCC1 was 
stable in the absence of matching levels of XPF, led us to 
hypothesise that, contrary to conventional understanding, 
this stability could result from ERCC1 homodimer 
formation. Theoretical support comes from the very high 
similarity at secondary and tertiary structural levels of the 
(HhH)2 folds of ERCC1 and XPF in the crystal structure 
of the ERCC1-XPF heterodimer [20], see Supplementary 
Figure 4A. In addition, archaeal XPF homodimers also 
interact via their central nuclease domains, and the 
crystal structure of the central domain of ERCC1 [19] 
has a strikingly similar fold to the nuclease domain of the 
archaeal Mus81/XPF homologue [41], see Supplementary 
Figure 4B.
We investigated this hypothesis following the co-
transfection of separate Flag- and Myc-tagged ERCC1 
constructs into A375 cells by immunoprecipitation with a 
magnetic bead-linked antibody to the Myc tag (Figure 4A). 
Non-transfected, Flag-tagged ERCC1 transfected-only and 
Myc-tagged ERCC1 transfected-only samples were used 
as controls. An additional co-transfection was set up to 
investigate the possibility that ERCC1 homodimerization 
may be affected by cisplatin treatment. Conventional 
western blotting was performed as before, with Flag-
tag antibody for the IP samples and Myc-tag antibody 
and Flag-tag antibody, together with B-actin antibody as 
the internal control, for the input samples. Flag-tagged 
ERCC1 was only seen after IP if co-transfected with Myc-
tagged ERCC1, showing that Flag-tagged ERCC1 was 
pulled down by the Myc-tagged ERCC1. Moreover, there 
was a band detected by the Flag-tag antibody at double 
the normal size of ERCC1 and the intensity of this band 
was increased after cisplatin treatment. In addition to this 
conventional western blot with the IP samples (SDS PAGE 
gel with boiled samples under reducing conditions), we 
ran a semi-native western blot (SDS PAGE gel, non-boiled 
and non-reduced samples) with the input samples using 
the ERCC1 antibody. In addition to endogenous ERCC1 
and overexpressed Flag- and Myc-tagged ERCC1 at the 
expected size for monomers, a band at double the size of 
ERCC1 was present in all ERCC1- transfected samples 
and this band was also increased in intensity after cisplatin 
treatment. We conclude that homodimerization of over-
expressed ERCC1 does indeed occur.
A further immunoprecipitation was carried out to 
investigate if ERCC1 homodimerization occurs through 
both (HhH)2 and central domains (Figure 4B). Full length 
Myc-tagged ERCC1 was co-transfected with Flag-tagged 
full-length ERCC1 or truncations (1-219, 96-297 and 220-
297) and immunoprecipitation was performed as before, 
with conventional western blots. For the IP samples, the 
Flag-tagged full-length ERCC1 monomer was pulled 
down by the Myc-tagged ERCC1 as before, together 
with a band of ERCC1 homodimer size, so confirming 
the previous result. Intriguingly, the Flag-tagged ERCC1 
(1-219) truncation lacking the (HhH)2 domain was also 
pulled down by Myc-tagged ERCC1, but with no band 
corresponding to the size of mixed ERCC1 homodimer. 
Truncations of Flag tagged ERCC1 (96-297) and ERCC1 
(220-297) were not pulled down and the results with 
the input samples again indicated that these truncations 
were much more unstable than the other ERCC1 
constructs. These results indicate that homodimerization 
of ERCC1 is likely through the central as well as the 
(HhH)2 domains, but that the central domain interaction 
is weaker. Moreover, in the input results panel, the level 
of full-length Myc-tagged ERCC1 was clearly reduced 
by co-transfection with Flag-tagged ERCC1 truncations, 
particularly the unstable ERCC1 (220-297).
Homodimerization of endogenous ERCC1
To investigate possible homodimerization of 
ERCC1 at endogenous expression levels, size exclusion 
chromatography was performed on native lysates from 
non-transfected control and cisplatin-treated A375 
melanoma cells. A semi-native blot was also performed 
to identify potential ERCC1 homodimers as well as the 
normal denaturing western blot. In addition to antibodies 
against ERCC1 and XPF, an anti-XPA antibody was 
used as a marker for NER complexes and an anti-EME1 
antibody was used for interstrand crosslink (ICL) repair 
complexes (Supplementary Figure 5). For the non-
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treated sample, the normal western blot (Supplementary 
Figure 5Aa) showed that the distribution of ERCC1 and 
XPF was very similar, with both peaking in fractions 
from 158-440 kD. This coincided with a small XPA 
peak, indicating that these are NER complexes. ERCC1 
and XPF were also present in higher molecular weight 
fractions extending beyond the largest marker at 689 
kD, which was the peak for the ICL complex marker 
protein EME1, indicating that ERCC1 and XPF in these 
fractions are engaged in ICL repair, rather than in NER. 
Figure 3: ERCC1 is ubiquitinated in a non-conventional lysine-independent manner. (A) 6xHis-tagged ubiquitin was co-
transfected into A375 cells with individual point mutants in the XPF-binding domain of ERCC1, where each of the five lysines was 
mutated to arginine, ERCC1 (K226R), (K243R), (K247R), (K281R) and (K295R). Wild-type ERCC1 was used as positive control. Each 
transfection was carried out in duplicate. After 24 h, one dish from each pair was exposed to MG132 (25 µΜ) for 5 h and then the in vivo 
ubiquitination assay was performed. Material purified on Ni beads was western blotted for ERCC1. A sample of the input material prior to 
purification was also blotted for ERCC1 and B-actin. The positions of the ubiquitinated ERCC1 ladder and of non-ubiquitinated ERCC1 
are indicated. Note the reduced levels of ERCC1 ubiquitination and of total ERCC1 in the MG132-exposed K226R and K281R mutants. 
(B) In vivo ubiquitin assay with point mutants ERCC1 (K226R) and (K281R), lysine combination mutants in the XPF binding domain, 
ERCC1 (K226, 295R) and (K247, 295R), and ERCC1 (5R), where all 5 Lysines were mutated to Arginine. Note again the reduced levels 
of ERCC1 ubiquitination and of total ERCC1 in the MG132-exposed K226R and K281R mutants, but that ubiquitination in the double 
mutant ERCC1 (K226, 281R) was not reduced. Ubiquitination was also not reduced in the ERCC1 (5R) multiple mutant. (C) Validation 
of a nucleotide excision repair (NER) assay for mutant ERCC1 constructs. ERCC1-null A375 melanoma cells plated into 96-well plates 
were co-transfected 24 h later with ERCC1 wild-type or deletion constructs, (1-219), (96-297) and (220-297), and a UV-damaged or 
non-damaged GFP plasmid with a control luciferase plasmid and then assayed for GFP and luciferase activity after a further 48 hr. NER 
activity is plotted as fold over background in non-transfected cells against amount of ERCC1 plasmid used in each transfection. Note the 
complete lack of NER activity with ERCC1 (1-219) and ERCC1 (220-297) plasmids. (D) Lysines in the XPF binding domain of ERCC1 
are not required for NER activity. NER assay with ERCC1 (WT) and point mutants (K226R), (K243R), (K247R), (K281R), (K295R) and 
multiple mutant (5R) in ERCC1-null A375 melanoma cells. Note that none of the ERCC1 mutants tested had significantly lower levels of 
NER activity than the wild-type construct.
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Figure 4: Homodimerization of overexpressed ERCC1 occurs and construct ERCC1 (220-297) can dramatically destabilise 
co-transfected wild-type ERCC1. (A) Flag-tagged wild-type ERCC1 was co-transfected with Myc-tagged wild-type ERCC1 in duplicate 
dishes of A375 cells. Non-transfected, ERCC1-Myc-only and ERCC1-Flag-only transfections were used as controls. After 24 h one of 
the co-transfected dishes was exposed to 25 µM cisplatin (CDDP) for 5 h. Immunoprecipitation was then performed with an antibody 
to the Myc tag linked to magnetic beads. Western blotting was performed for the IP samples with anti-Flag antibody on a conventional 
denaturing gel. To visualise intact ERCC1 homodimers, a semi-native western blot was run with non-reduced and non-boiled input samples 
and blotted with an anti-ERCC1 antibody. Blots of input samples, run on conventional denaturing gels, with anti-Flag, anti-Myc and anti-
B-actin antibodies are also shown. The positions of ERCC1-Flag monomers and homodimers, IgG heavy and light chains and a cross 
reacting band are all indicated. Note: ERCC1-Flag monomers and homodimers are present in the co-transfected IP samples, but not in the 
ERCC1-Flag only transfection control, and ERCC1 homodimers are also present on the blot of input samples on the semi-native gel. (B) 
Myc-tagged wild-type ERCC1(1-297) was co-transfected with Flag-tagged wild-type ERCC1(1-297) and Flag-tagged truncations (1-219), 
(96-297) and (220-297). 24 h after transfection, immunoprecipitation was performed with an antibody to the Myc tag linked to magnetic 
beads and western blotting was performed for the IP samples as before with anti-Flag antibody. Mol. wt. markers (kDa) are shown. Blots 
of input samples run on conventional denaturing gels with anti-Flag, anti-Myc and anti-B-actin antibodies are also shown. The positions 
of ERCC1(1-297)-Flag monomers and homodimers, ERCC1(1-219)-Flag monomers and of IgG heavy and light chains are indicated. Note 
that ERCC1-Flag monomers and homodimers are again present in the ERCC1(1-297)-Flag and ERCC1(1-297)-Myc co-transfected IP 
sample, that ERCC1(1-219)-Flag was also pulled down by ERCC1(1-297)-Myc and that the level of Myc-tagged wild-type ERCC1 was 
greatly reduced in the co-transfection with ERCC1 (220-297)-Flag.
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ERCC1, but not XPF monomers were also present in 
smaller fractions extending down to 75 kD. The semi-
native western blot (Supplementary Figure 5Ab) was 
very similar but, intriguingly, there was also a band at 
ERCC1 homodimer size in two of the same fractions of 
around 80 kD as the ERCC1 monomer sub-peak. For 
the cisplatin-treated sample, the normal western blot 
(Supplementary Figure 5Ba) showed more distinct peaks 
for ERCC1 and XPF in ICL repair complexes, in addition 
to the NER complex peaks. In the semi-native western blot 
(Supplementary Figure 5Bb), bands of ERCC1 homodimer 
size were no longer present in fractions of around 80 kD, 
instead multiple ERCC1 bands were now present in NER 
fractions around 158 kD, including possible ERCC1-XPF 
heterodimers (ERCC1 33 kD, XPF 104 kD), and a band 
at around 80kD, the size of putative ERCC1 homodimers. 
We interpret these data as supporting the existence of 
ERCC1 homodimers at endogenous expression levels.
Levels of endogenous ERCC1 and XPF are both 
reduced by expression of the ERCC1 (220-297) 
peptide
Having demonstrated that the ERCC1 (220-297) 
peptide can destabilise over-expressed levels of ERCC1 
and XPF, we next investigated whether it was also able to 
reduce endogenous levels of both proteins and so inhibit 
NER and enhance the sensitivity of cancer cells to DNA 
damaging agents. A375 melanoma cells and MRC5v1 
immortalised human fibroblasts were transfected with the 
Flag-tagged ERCC1 (220-297) truncation plasmid and 
G418 selection was applied for the neo marker on the 
plasmid. Resistant colonies were screened for expression 
of the Flag tag and two Flag tagged- ERCC1 (220-297) 
expressing clones of each cell type were analysed by 
western blotting (Figure 5 and Supplementary Figure 6). 
Levels of ERCC1 and XPF were reduced by more than 
50% in both A375 clones analysed compared to control 
A375 cells, while levels of another NER protein (XPA) 
and three ICL repair proteins (RAD51, EME1 and SLX4) 
were unaffected (Figure 5A and 5B). ERCC1 and XPF 
were also reduced by more than 60% in both MRC5v1 
clones (Figure 5A and 5C). 
The ERCC1 (220-297) peptide inhibits 
nucleotide excision repair and increases 
sensitivity to DNA damaging agents
The NER assay was carried out, as described in 
Materials and Methods, on the same two Flag-tagged 
ERCC1 (220-297) -expressing clones of A375 and 
MRC5v1 as above. Cells in 96-well plates were co-
transfected with UV-damaged or non-damaged GFP 
plasmids and control luciferase plasmids. 24 hr later, the 
GFP and luciferase activity were measured and NER 
activity was calculated (Figure 6A). Compared with the 
control cells, NER activity of both A375 ERCC1 (220-297) 
clones was reduced by 40%, while the reduction for the 
two MRC5v1 clones was greater at 65% and 85%. These 
reductions in NER activity relative to the cell type control 
were all highly significant (p < 0.025 by Student’s t test). 
To determine whether these large ERCC1 (220-
297) peptide-induced reductions in NER activity resulted 
in increased sensitivity to DNA damaging agents, we 
carried out standard 5-day growth assays following 
UVC irradiation (Figure 6B). We chose this agent 
initially because UVC-induced DNA damage is repaired 
exclusively by NER. The IC50 for A375 cells was 11.4 
Jm-2 (95% confidence interval 10.9-11.9 Jm-2), while IC50s 
for A375-E (220-297) clones #1, 8.7 (95% confidence 
interval 8.4-9.0), and #6, 8.5 (95% confidence interval 8.4-
8.7) Jm-2 were 25% lower. The IC50 for MRC5v1 cells was 
8.3 (7.9-8.8) Jm-2, while the IC50 for MRC5v1-E (220-
297) clone #2 was 45% lower at 4.5 Jm-2 (95% CI 4.4-4.6) 
and the IC50 for clone #7 was 35% lower at 5.3 Jm-2 (95% 
CI 5.0-5.6). These increases in UV sensitivity relative 
to the cell type controls were all significant (p < 0.05). 
The effect of the ERCC1 (220-297) peptide-induced 
reduction in levels of ERCC1-XPF on sensitivity to the 
chemotherapeutic cisplatin was less pronounced. The IC50 
value for A375-E (220-297) clone #1 (0.81 µM) was 15% 
less than the A375 control (0.96 µM), IC50 for clone #6 
(0.86 µM) was 10% lower, but these differences were 
not significant (p > 0.05) (Figure 6C). The MRC5v1-E 
(220-297) clones showed no obvious increased sensitivity 
compared to control MRC5v1 cells (data not shown). 
Lower levels of ERCC1-XPF activity are known to be 
sufficient for the repair of cisplatin-induced ICLs than are 
required for NER [42]. Nevertheless, we conclude that the 
ERCC1 (220-297) peptide causes major reductions in NER 
activity and increased sensitivity to DNA damaging agents.
DISCUSSION
Chemotherapy with DNA damaging agents remains 
the mainstay of current therapy for the majority of common 
cancers. The structure-specific endonuclease ERCC1-XPF 
is involved in the repair of DNA damage caused by many 
of these agents and there has been much interest in the 
use of ERCC1-XPF as a predictive marker of response to 
chemotherapy (reviewed in [4]). We validated ERCC1 as a 
therapeutic target by showing that a genetically engineered 
ERCC1-deficient mouse model of melanoma was uniquely 
sensitive to the chemotherapeutic cisplatin [23]. The 
ERCC1-deficient melanoma cells used were 10-fold 
more sensitive to cisplatin, leading us to conclude that 
biochemical inhibition of ERCC1-XPF would need to 
block > 90% of NER activity and achieve near 10-fold 
increased sensitivity to cisplatin to be of therapeutic value. 
As a guide, siRNA against ERCC1 or XPF resulted in 
only 2-3-fold increased cisplatin sensitivity [22]. Despite 
the availability of structural information and much 
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Figure 5: Levels of endogenous ERCC1 and XPF are both reduced by transfection with the ERCC1 (220-297) 
truncation. A375 human melanoma cells and MRC5v1 immortalised human fibroblasts were transfected with the Flag-tagged ERCC1 
(220-297) truncation, selection for the neo marker present on this plasmid was applied with G418 (2 mg/ml) and clones expressing the Flag-
tag were identified. (A) Western blots of control A375 cells, A375 ERCC1 (220-297) expressing clones #1 and #6, control MRC5v1 cells 
and MRC5v1 ERCC1 (220-297) expressing clones #2 and #7. Blotting for ERCC1 (33 kDa), XPF (104 kDa), XPA (40 kDa, NER marker 
protein), RAD51 (37 kDa), EME1 (63 kDa) and SLX4 (200 kDa, all interstrand crosslink repair marker proteins), Flag tag (detecting Flag-
tagged ERCC1 (220-297), 11.5 kDa) and beta-actin (42 kDa). (B) Histogram showing the level of each protein blotted in A375 ERCC1 
(220-297) clones #1 and #6, expressed relative to B-actin and normalized to the level in A375 control cells. (C) Histogram showing the 
level of each protein blotted in MRC5v1 ERCC1 (220-297) clones #2 and #7, expressed relative to B-actin and normalized to the level in 
MRC5v1 control cells. Note the reduced levels of ERCC1 and XPF in all clones.
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Figure 6: Expression of the ERCC1 (220-297) peptide inhibits nucleotide excision repair and sensitises cells to UV-
induced DNA damage and cisplatin. (A) Inhibition of NER. Cells from A375, A375 ERCC1 (220-297) clones #1 and #6, MRC5v1 
and MRC5v1 ERCC1 (220-297) clones #2 and #7 were plated in 96-well plates, co-transfected 24 hr later with UV-damaged or non-
damaged GFP and control luciferase plasmids and assayed for GFP and luciferase activity after a further 24 hr. Values plotted are the mean 
NER activity (±SEM) from three independent experiments as a percentage of activity in normal control cells. (B) Increased sensitivity 
to UV-induced DNA damage. 104 cells from A375, A375 ERCC1 (220-297) clones #1 and #6, MRC5v1 and MRC5v1 ERCC1 (220-297) 
clones #2 and #7 were plated in duplicate 35 mm dishes. 24 h later dishes were exposed to 1-20 Jm-2 UVC. 5 days later dishes were fixed and 
stained with Sulphorhodamine B [53]. For each cell line, growth is expressed as the percentage of the non-irradiated control. Values plotted 
are mean % growth (± SEM) from two independent experiments. (C) Increased sensitivity to cisplatin. A standard 5-day SRB growth assay 
in 96-well plates was carried out. 500 cells/well from A375, A375 ERCC1 (220-297) clones #1 and #6 were plated in quadruplicates and 
exposed to 25-1600 nM cisplatin (CDDP) for five days before plates were fixed and stained. For each cell line, growth is expressed as the 
percentage of the non-cisplatin-treated control. Values plotted are mean % growth (± SEM) from two independent experiments.
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endeavour we [27–29] and others [24–26] had been unable 
to identify ERCC1-XPF inhibitors of sufficient potency 
and specificity in preclinical models to justify further 
development.
Initial in silico screening identified a compound 
binding to the XPA-interacting pocket of ERCC1 that 
enhanced the UV sensitivity of human colon cancer cells 
by 2-fold, but had a weaker effect on cisplatin sensitivity 
[24, 25]. Our best in silico screening-derived inhibitor 
of the interaction between ERCC1 and XPF was active 
in an NER assay in melanoma cells (IC50 20 µM), but 
caused only a small (1.3-fold) reduction in the cisplatin 
IC50 [27]. While an independently derived ERCC1-XPF 
interaction inhibitor caused modest enhanced sensitivity 
to cisplatin in two cancer cell lines and was apparently 
able, at high concentrations (up to 500 µM), to disrupt the 
ERCC1-XPF interaction in cell extracts [26]. We had more 
success using high throughput screening to identify XPF 
endonuclease inhibitors with specificity for ERCC1-XPF 
over related endonucleases [27]. The two best inhibitors 
gave strong inhibition of NER in melanoma cells (IC50 < 
10 µM), but again only increased the cisplatin sensitivity 
by up to 2-fold. While extensive medicinal chemistry on 
the two compounds was able to identify derivatives with 
improved activity against ERCC1-XPF endonuclease 
activity in an in vitro assay (IC50 < 1 µM), with > 10-
fold selectivity for ERCC1-XPF over the related FEN-1 
endonuclease, there was no improvement in the 2-fold 
increased sensitivity to cisplatin [28, 29].
The investigation of post-translational modification 
and stability reported here led us to an alternative approach 
to target ERCC1-XPF. However, while this work was 
in progress, more encouraging results for conventional 
ERCC1-XPF inhibitors have been reported [43, 44]. In 
particular, an ERCC1-XPF endonuclease inhibitor (IC50 
< 1 µM), with specificity against another endonuclease 
and, despite only showing ~2-fold enhanced sensitivity 
to cisplatin, potentiated cisplatin activity in a lung cancer 
xenograft model [44].
We found that the stability of ERCC1, but not of XPF, 
was regulated by ubiquitination. The consistent accumulation 
of ERCC1, but not XPF, after proteasome inhibitor 
MG132 exposure strongly indicated the involvement of 
the ubiquitin-dependent proteasome degradation pathway. 
Three ERCC1 lysine residues were previously found 
to be ubiquitinated in a global mass spectrometry assay 
(phosphosite plus, http://www.phosphosite.org/homeAction.
do). Our ubiquitin assays focussed on the initial rungs of the 
ERCC1 ubiquitination ladder and we found that ERCC1 is 
likely modified by a chain formed by at least four ubiquitins. 
Although the mechanism of ERCC1 ubiquitination and the 
role this plays in the stability of ERCC1-XPF has not been 
studied previously, the USP45 protein has been found to 
bind to and deubiquitinate ERCC1. USP45 knockout cells 
showed reduced levels of NER and increased sensitivity to 
UV irradiation [45].
Polyubiquitination usually commences with an 
isopeptide linkage between the ubiquitin C-terminal 
carboxyl residue and the epsilon amino group of a Lys 
residue on the target. Additional ubiquitins are then added 
via any of the seven Lys residues (Lys6, Lys11, Lys27, 
Lys29, Lys33, Lys48 and Lys63), or the amino terminal 
Met residue [46]. Although polyubiquitination via Lys48 
is most commonly involved in proteasome-dependent 
degradation of the target protein [47], our assays with 
ubiquitin Lys point and combination mutants and an 
antibody against linear ubiquitin chains indicated that, 
instead, both polyubiquitination via Lys33 and linear 
chain polyubiquitination of ERCC1 were occurring. 
The unexpected ubiquitination of ERCC1 observed with 
the human mutant ubiquitin construct, where all seven 
Lys residues were mutated, was also indicative of linear 
chain polyubiquitination [36]. These results indicate that 
an altered ERCC1 ubiquitination pattern can arise from 
two different types of alteration to ubiquitin. The first 
is mutation (Lys to Arg) of one of the Lys residues of 
ubiquitin that is involved in the ERCC1 ubiquitination 
process. Our data suggest that Lys33 is the only one 
of the seven Lys residues of ubiquitin that is involved 
in ERCC1 ubiquitination. The second is a structural 
alteration to ubiquitin resulting from alterations to 
one or more ubiquitin residues that affect the way that 
ubiquitin is processed by the ubiquitination machinery. 
Thus, the three amino acid difference between plant and 
human ubiquitin 7R results in a major difference in the 
ERCC1 ubiquitination pattern: a normal pattern with 
human 7R, but no ubiquitination with plant 7R. We 
suggest that, by extension, the Lys33 to Arg mutation 
within a normal human ubiquitin structure affects the 
ERCC1 ubiquitination pattern, but has no effect on the 
ubiquitination pattern in the altered 7R ubiquitin structure.
Using a series of non-tagged and Flag-tagged 
ERCC1 deletion constructs we showed that the XPF-
binding domain of ERCC1, residues (220-297), was 
essential for ubiquitin-dependent proteasome degradation 
by increased intensity of the ubiquitination ladder 
following exposure to MG132 for all constructs containing 
this region and by the very low levels of protein detected 
in input samples from constructs containing the (220-297) 
domain only. ERCC1 residues (1-95) were not necessary 
for ubiquitin-dependent proteasome degradation, but 
instead helped to stabilise the protein. All ERCC1 proteins 
studied were predominantly located in nuclei, allowing 
us to exclude the possibility that the ERCC1 truncations 
were interacting differently with the ubiquitin-dependent 
proteasome degradation pathway due to an altered 
subcellular location.
By over-expressing XPF in addition to ERCC1 
we showed that the ubiquitin-dependent proteasome 
degradation of over-expressed ERCC1 was not simply an 
artefact caused by lack of its XPF binding partner. There 
was no evidence that XPF was also a substrate for the 
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ubiquitin-dependent proteasome degradation pathway. 
Instead, the presence of over-expressed XPF was dependent 
on over-expression of ERCC1 and its stability was reduced 
by ubiquitination of ERCC1. This could be an effective 
regulatory mechanism to prevent unwanted endonuclease 
activity (encoded by XPF) on non-damaged DNA. 
Although examination of the crystal structure 
between the double helix-hairpin-helix (HhH)2 domains 
of ERCC1 and XPF [20] indicated the potential for 
polyubiquitination of any of the five Lys residues present 
in ERCC1 (220-297) to destabilise the binding of ERCC1 
to XPF, none of the Lys point and combination mutants 
prevented ERCC1 polyubiquitination and we concluded 
that the proteasome-dependent degradation of ERCC1 
involves non-conventional, lysine-independent ubiquitin 
modification of the XPF-binding domain. Serine hydroxyl 
and cysteine thiol groups of the substrate can also be 
modified by ubiquitin [37, 38]. Using a transfection-based 
NER assay [27] that we first validated for use in ERCC1-
null A375 cells by demonstrating the essential roles of the 
central and XPF binding domains of ERCC1 for NER in 
the assay, we also found that none of the five lysines were 
essential for NER. 
Our most unexpected finding was the clear 
demonstration that over-expressed ERCC1 can form 
homodimers. Heterodimerisation of ERCC1 with XPF 
had been considered essential for the stability of both 
proteins [16–18], although more recent siRNA experiments 
indicated that, while XPF protein levels were decreased 
when ERCC1 was knocked down, the converse was not 
true [22]. Our homodimer hypothesis arose when we found 
that over-expressed ERCC1 was stable in the absence of 
matching levels of XPF and was buoyed by the very high 
structural similarity between both the (HhH)2 and central 
domains of ERCC1 and XPF [19, 20, 41]. Following co-
transfection of separate Flag- and Myc-tagged ERCC1 
constructs and immunoprecipitation with a magnetic 
bead-linked antibody to the Myc tag, we found that Flag-
tagged ERCC1 was specifically pulled down by the Myc-
tagged ERCC1. Both Flag-tagged ERCC1 monomers and 
dimers were present on the denaturing western blot of the 
IP material and on the semi-native blot of input material, 
indicating an extremely strong homodimer interaction. 
Further immunoprecipitations between Flag-tagged 
ERCC1 truncations and full-length Myc-tagged ERCC1 
showed that the central as well as the (HhH)2 domains were 
involved in homodimerisation, but that the central domain 
interaction was weaker, such that mixed Flag-tagged 
ERCC1 (1-219)/ Myc-tagged ERCC1 (1-297) homodimers 
could not be seen on the denaturing western blot.
Support for ERCC1 homodimerization also 
occurring at endogenous expression levels came from size 
exclusion chromatography. A semi-native western blot on 
native lysates from control A375 melanoma cells detected 
bands of ERCC1 homodimer size in two size fractions of 
around 80 kD. Following cisplatin treatment the putative 
ERCC1 homodimer bands had moved to higher molecular 
weight fractions of around 158 kD where NER complexes 
were located. The existence of ERCC1 homodimers at 
endogenous expression levels can also help to explain 
our initial result, where exposure to proteasome inhibitor 
MG132 resulted in accumulation of ERCC1 but not XPF. 
A substantial ERCC1 homodimer pool in addition to 
ERCC1-XPF heterodimers would be expected to lead to 
greater accumulation of ERCC1 than XPF after MG132 
treatment, particularly if the ERCC1 homodimer pool also 
turned over more rapidly. This could also explain the result 
after cycloheximide exposure, where levels of ERCC1 
dropped more rapidly than XPF.
We have provided structural information to support 
homodimerization occurring through the same strong 
hydrophobic and H-bonding interactions that operate to 
hold ERCC1-XPF heterodimers together. Whilst we have 
not determined the function of ERCC1 homodimerization, 
we consider that it could provide an alternative way to 
stabilise and store ERCC1 that serves to prevent unwanted 
non-repair-related endonuclease activity that resides with 
XPF in ERCC1-XPF heterodimers.
When the ERCC1 (220-297) peptide and XPF 
were overexpressed together (Figure 2E), there was a 
clear effect of the ERCC1 (220-297) peptide on reducing 
XPF levels. Whereas in the double-tagged ERCC1 
homodimerization experiment, when the ERCC1 (220-
297) peptide was overexpressed together with Myc-tagged 
ERCC1 wild-type (1-297) protein, but with endogenous 
levels of XPF (Figure 4B), there was a clear effect of the 
ERCC1 truncation on reducing levels of the overexpressed 
Myc-tagged ERCC1 wild-type protein, but why was 
there no observable effect on endogenous levels of XPF? 
We believe that overexpression of the target protein for 
destabilisation (XPF in the first instance, Myc-tagged 
ERCC1 wild-type protein in the second case) enlarges the 
detection window and so makes it easier to observe the 
destabilising effect of the ERCC1 (220-297) peptide in 
our transient transfection assays. We have shown that the 
ERCC1 (220-297) peptide is polyubiquitinated and rapidly 
degraded. Our results suggest that when newly synthesized 
ERCC1 (220-297) peptide dimerizes with either ERCC1 
wild-type or XPF monomers via their C-terminal domains, 
the rapid polyubiquitination of the ERCC1 (220-297) 
monomer targets the resulting ERCC1 homodimers or 
ERCC1-XPF heterodimers for proteasome degradation.
These observations led us to investigate whether 
the ERCC1 (220-297) peptide could also destabilise 
endogenous ERCC1 and XPF in stably transfected cells. 
Levels of ERCC1 and XPF were indeed reduced by 
more than 50% in clones of A375 melanoma cells and 
MRC5v1 immortalised human fibroblasts expressing the 
Flag-tagged ERCC1 (220-297) truncation, while levels 
of other NER and ICL repair proteins were unaffected. 
This resulted in a 40% reduction in NER activity in both 
A375 ERCC1 (220-297) clones and a greater reduction 
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(65 and 85%) in the two MRC5v1 ERCC1 (220-297) 
clones. In our NER assay the DNA repair activity of 
control A375 melanoma cells was four-fold higher than 
MRC5v1 fibroblast cells (data not shown). In addition to 
illustrating the importance of NER to this cancer type, it 
could also explain the greater ERCC1 (220-297) peptide-
induced reduction in NER activity in MRC5v1 cells.
The ideal DNA damaging agent to show the 
effect of targeting ERCC1-XPF activity in cancer cells 
is short wave UVC irradiation which causes damage 
that is repaired exclusively by NER. The reduced 
levels of NER we induced did indeed lead to increased 
sensitivity to UVC-induced DNA damage. The IC50 
values for the two A375-E (220-297) clones were 25% 
lower than for the A375 control, while IC50 values the 
MRC5v1-E (220-297) clones were 45% and 35% lower 
than for the MRC5v1 control. We also used a common 
chemotherapeutic, cisplatin, which causes multiple forms 
of DNA damage (monofunctional adducts and intrastrand 
crosslinks that are repaired by NER and interstrand 
crosslinks whose repair requires the involvement of a 
number of different repair pathways), in addition to also 
damaging proteins and other cellular components. Lower 
levels of ERCC1-XPF activity are known to be sufficient 
for the repair of cisplatin-induced interstrand crosslinks 
than are required for NER [42]. So the less pronounced 
effect of the ERCC1 (220-297) peptide-induced reduction 
in levels of ERCC1-XPF on sensitivity to cisplatin was 
not unexpected. Higher levels of the ERCC1 (220-297) 
peptide would be expected to drive the larger reductions 
in ERCC1-XPF levels needed to cause bigger increases in 
cisplatin sensitivity. 
Although our ERCC1 ubiquitination studies were only 
carried out on human melanoma cells, we also demonstrated 
that the ability of the ERCC1 (220-297) peptide to destabilise 
both ERCC1 and XPF in human fibroblasts. This, coupled 
with the report that inactivating the USP45 protein that 
deubiquitinates ERCC1 in human myelogenous leukaemia 
and osteosarcoma cells leads to reduced levels of NER and 
increased sensitivity to UV irradiation [45], suggests that our 
therapeutic strategy is likely applicable to a wide range of 
human cancers. While delivering the 78-amino acid ERCC1 
(220-297) peptide for therapeutic use would constitute 
a considerable challenge, recent developments with cell 
penetrating peptides suggest that the size in itself is not 
prohibitive and that such an approach merits consideration 
[48]. While this work was being carried out, another study 
[49] reported that expression of the XPF-interacting domain 
of ERCC1 in cancer cells resulted in increased sensitivity to 
DNA damaging agents, but without any investigation of the 
mechanism involved.
So, in the course of investigating the role of the 
proteasome-dependent protein degradation pathway in 
the stability of the key DNA repair protein ERCC1-XPF 
and the mechanism of its ubiquitination, we saw that 
XPF was dependent on ERCC1 for stability and made the 
surprising discovery that ERCC1 can also homodimerize 
in mammalian cells. This interaction, principally through 
the (HhH)2, but also involving the central domains of 
ERCC1, could be a mechanism to keep ERCC1 stable 
by preventing the ubiquitination of the key residue(s) 
in the (HhH)2 domain, without the risk of unwanted 
endonuclease activity from ERCC1-XPF heterodimers. 
We were able to exploit the instability of the ERCC1 
(220-297) peptide to destabilise endogenous levels of 
both ERCC1 and XPF, resulting in major reductions in 
NER activity and increased sensitivity to DNA damaging 
agents. Given the importance of ERCC1-XPF as a target 
in cancer cells and the current lack of small molecule 
inhibitors with sufficient potency and specificity to enter 
clinical trials, if high levels of this peptide or a smaller 
mimic could be achieved in cancer cells, then it could 
represent a powerful new alternative therapeutic approach. 
MATERIALS AND METHODS
Mammalian cells
Human A375 and C32 melanoma cells, 
authenticated by short tandem repeat profiling, were 
obtained from The European Collection of Cell Cultures 
(Salisbury, UK). An ERCC1 null derivative of A375 
was generated using CRISPR/Cas9 genome editing and 
the loss of ERCC1 protein was confirmed by western 
blotting. The MRC5v1 cell line was kindly provided 
by Prof Alan Lehmann, Genome Damage and Stability 
Centre, University of Sussex. It was obtained by SV40 
transformation of primary human fibroblasts [50]. All 
experiments were performed on cultures within 10 
passages of their supply. Cells were maintained in DMEM 
medium (41965; Life Technologies Ltd., Paisley, UK), 
supplemented with 10% FCS, Non-Essential Amino 
Acids (11140-035; Life Technologies Ltd.), 1 mM Sodium 
Pyruvate, 2 mM L-glutamine and Penicillin (100 U/ml) 
–Streptomycin (100 mg/ml) at 37°C, 5% CO2.
Plasmids
Full-length and truncated human ERCC1 constructs 
in mammalian expression vectors pcDNA3.1(-) /myc-
His A (Life Technologies Ltd.) and p3xFLAG-CMV-14 
(Sigma-Aldrich, Poole, UK) were constructed by standard 
cloning techniques. ERCC1 point mutants and combination 
mutants in pcDNA3.1(-)/myc-His A were generated using 
QuikChange™ Site-Directed (200518, Agilent Technologies 
UK Ltd., Edinburgh, UK) and Multi Site-Directed 
(200515, Agilent Technologies UK Ltd.) Mutagenesis 
Kits. Human 6x-His-Ubiquitin(WT) and plant 6x-His-
Ubiquitin(7R) constructs in pcDNA3 (Life Technologies 
Ltd.) were supplied by Dr Lesley Stark (University of 
Edinburgh) [51]. Point and combination mutants of Human 
6x-His-hUbiquitin(WT) were generated by site-directed 
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mutagenesis as above. Human XPF (ERCC4) expressing 
plasmid pCMV6-ENTRY-ERCC4 (C-terminal Myc and 
DDK-tagged) was obtained from Cambridge Bioscience 
Ltd. (Cambridge, UK). The structures of all plasmids used 
were verified by DNA sequencing. See Supplementary 
Information for more details of constructs. Plasmids were 
transfected into A375 or MRC5v1 cells with Lipofectamine 
2000, using conditions recommended by the supplier (Life 
Technologies Ltd).
Western blotting
Protein extraction for denaturing SDS gels was 
carried out on ice using RIPA buffer (25 mM Tris-HCl pH 
7.2, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 
1 mM EDTA, 20 mM NaF, 100 µM orthovanadate), 
with Roche complete protease inhibitor cocktail (Roche 
Products Ltd., Welwyn Garden City, UK) and western 
blotting was carried out as described [52]. Details of 
denaturing and semi-native gel systems and antibodies 
used are given in Supplementary Information.
Ubiquitination assay
A375 cells expressing 6xHis-tagged ubiquitin and 
ERCC1 target constructs were lysed in 6 M guanidinium-
HCl containing denaturing buffer and incubated 
overnight with Ni-NTA-agarose beads (30210, Qiagen 
Ltd., Manchester, UK). The beads were washed with 
6 M guanidinium-HCl containing- and then 8 M urea-
containing denaturing buffers. His-tagged ubiquitinated 
protein bound to the beads was eluted with 200 mM 
imidazole-containing buffer and western blotted. See 
Supplementary Information for full details.
Immunocytochemistry, immunoprecipitation, 
size exclusion chromatography
See Supplementary Information for details of these 
assays.
Nucleotide excision repair assays
Details and validation of the transfection-based 
assay to measure NER activity in A375 melanoma cells, 
involving UV-irradiated GFP and control luciferase 
plasmids, have been described [27]. Modifications of 
the assay to measure NER from ERCC1 constructs 
transfected into ERCC1-deficient A375 cells are described 
in Supplementary Information.
Abbreviations
CDDP, cisplatin; GFP, green fluorescent protein; 
(HhH)2, paired helix-hairpin-helix; ICL, interstrand 
crosslink; NER, nucleotide excision repair; SRB, 
Sulphorhodamine B.
Authors’ contributions
LY: Study design, most experimental work and 
results interpretation, participated in manuscript writing. 
AMR: some of the experimental work and results 
interpretation. DWM: Project supervision and manuscript 
writing.
ACKNOWLEDGMENTS
We are grateful to Martin Wear (Centre for 
Translational and Chemical Biology, School of Biological 
Sciences, University of Edinburgh) for carrying out the 
size exclusion chromatography. 
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest.
GRANT SUPPORT
LY was supported by the China Scholarships 
Council and The University of Edinburgh.
REFERENCES
1. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson 
AR, Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van 
Leeuwen W, Theil AF, Vermeulen W, van der Horst GT, et 
al. A new progeroid syndrome reveals that genotoxic stress 
suppresses the somatotroph axis. Nature. 2006; 444:1038–43. 
https://doi.org/10.1038/nature05456.
2. Vermeij WP, Dollé ME, Reiling E, Jaarsma D, Payan-Gomez 
C, Bombardieri CR, Wu H, Roks AJ, Botter SM, van der 
Eerden BC, Youssef SA, Kuiper RV, Nagarajah B, et al. 
Restricted diet delays accelerated ageing and genomic stress 
in DNA-repair-deficient mice. Nature. 2016; 537:427–31. 
https://doi.org/10.1038/nature19329.
3. Sepe S, Milanese C, Gabriels S, Derks KW, Payan-Gomez 
C, van IJcken WF, Rijksen YM, Nigg AL, Moreno S, 
Cerri S, Blandini F, Hoeijmakers JH, Mastroberardino 
PG. Inefficient DNA repair is an aging-related modifier of 
parkinson’s disease. Cell Reports. 2016; 15:1866–75. https://
doi.org/10.1016/j.celrep.2016.04.071.
4. McNeil EM, Melton DW. DNA repair endonuclease 
ERCC1-XPF as a novel therapeutic target to overcome 
chemoresistance in cancer therapy. Nucleic Acids Res. 2012; 
40:9990–10004. https://doi.org/10.1093/nar/gks818.
5. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 
expression is a predictor of survival in resected patients with 
non-small cell lung cancer. Chest. 2005; 127:978–83. https://
doi.org/10.1378/chest.127.3.978.
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, André 
F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper 
HH, Stahel R, Sabatier L, Pignon JP, et al, and IALT Bio 
Oncotarget18www.impactjournals.com/oncotarget
Investigators. DNA repair by ERCC1 in non-small-cell 
lung cancer and cisplatin-based adjuvant chemotherapy. 
N Engl J Med. 2006; 355:983–91. https://doi.org/10.1056/
NEJMoa060570.
 7. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B. 
ERCC1 and BRCA1 mRNA expression levels in metastatic 
malignant effusions is associated with chemosensitivity to 
cisplatin and/or docetaxel. BMC Cancer. 2008; 8:97. https://
doi.org/10.1186/1471-2407-8-97.
 8. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-
based treatments for advanced non-small cell lung cancer, 
is low/negative ERCC1 expression better than high/positive 
ERCC1 expression? A meta-analysis. Lung Cancer. 2010; 
70:63–70. https://doi.org/10.1016/j.lungcan.2010.05.010.
 9. Bai ZL, Wang YY, Zhe H, He JL, Hai P. ERCC1 mRNA 
levels can predict the response to cisplatin-based concurrent 
chemoradiotherapy of locally advanced cervical squamous 
cell carcinoma. Radiat Oncol. 2012; 7:221. https://doi.
org/10.1186/1748-717X-7-221.
10. Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, 
Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath 
S, Martins RG. ERCC1 is a prognostic biomarker in locally 
advanced head and neck cancer: results from a randomised, 
phase II trial. Br J Cancer. 2013; 109:2096–105. https://doi.
org/10.1038/bjc.2013.576.
11. DeLoia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, 
Nuttall K, Krivak TC, Niedernhofer LJ. Comparison of 
ERCC1/XPF genetic variation, mRNA and protein levels 
in women with advanced stage ovarian cancer treated with 
intraperitoneal platinum. Gynecol Oncol. 2012; 126:448–54. 
https://doi.org/10.1016/j.ygyno.2012.05.006.
12. Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata 
K, Takahashi T, Sekido Y, Yatabe Y. mRNA expression 
of RRM1, ERCC1 and ERCC2 is not associated with 
chemosensitivity to cisplatin, carboplatin and gemcitabine in 
human lung cancer cell lines. Respirology. 2008; 13:510–17. 
https://doi.org/10.1111/j.1440-1843.2008.01302.x.
13. Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz 
RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula 
V, Murray S, Lambropoulos A, Aravantinos G, Markou 
K, Athanassiou E, et al. MMP9 but not EGFR, MET, 
ERCC1, P16, and P-53 Is associated with response to 
concomitant radiotherapy, cetuximab, and weekly cisplatin 
in patients with locally advanced head and neck cancer. 
J Oncol. 2009; 2009:305908. https://doi.org/https://doi.
org/10.1155/2009/305908.
14. Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong 
DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, 
Krivak TC. Pre-treatment tumor expression of ERCC1 in 
women with advanced stage epithelial ovarian cancer is not 
predictive of clinical outcomes: a Gynecologic Oncology 
Group study. Gynecol Oncol. 2012; 125:421–26. https://doi.
org/10.1016/j.ygyno.2012.01.008.
15. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir 
R, Wood RD, Niedernhofer LJ. Immunodetection of DNA 
repair endonuclease ERCC1-XPF in human tissue. Cancer 
Res. 2009; 69:6831–38. https://doi.org/10.1158/0008-5472.
CAN-09-1237.
16. de Laat WL, Sijbers AM, Odijk H, Jaspers NG, Hoeijmakers 
JH. Mapping of interaction domains between human 
repair proteins ERCC1 and XPF. Nucleic Acids Res. 1998; 
26:4146–52. https://doi.org/10.1093/nar/26.18.4146.
17. Biggerstaff M, Szymkowski DE, Wood RD. Co-correction 
of the ERCC1, ERCC4 and xeroderma pigmentosum group 
F DNA repair defects in vitro. EMBO J. 1993; 12:3685–92.
18. van Vuuren AJ, Appeldoorn E, Odijk H, Yasui A, Jaspers NG, 
Bootsma D, Hoeijmakers JH. Evidence for a repair enzyme 
complex involving ERCC1 and complementing activities 
of ERCC4, ERCC11 and xeroderma pigmentosum group F. 
EMBO J. 1993; 12:3693–701.
19. Tsodikov OV, Enzlin JH, Schärer OD, Ellenberger T. Crystal 
structure and DNA binding functions of ERCC1, a subunit 
of the DNA structure-specific endonuclease XPF-ERCC1. 
Proc Natl Acad Sci USA. 2005; 102:11236–41. https://doi.
org/10.1073/pnas.0504341102.
20. Tripsianes K, Folkers G, Ab E, Das D, Odijk H, Jaspers 
NG, Hoeijmakers JH, Kaptein R, Boelens R. The structure 
of the human ERCC1/XPF interaction domains reveals 
a complementary role for the two proteins in nucleotide 
excision repair. Structure. 2005; 13:1849–58. https://doi.
org/10.1016/j.str.2005.08.014.
21. Choi YJ, Ryu KS, Ko YM, Chae YK, Pelton JG, Wemmer 
DE, Choi BS. Biophysical characterization of the interaction 
domains and mapping of the contact residues in the XPF-
ERCC1 complex. J Biol Chem. 2005; 280:28644–52. https://
doi.org/10.1074/jbc.M501083200.
22. Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, 
Patrick SM. Downregulation of XPF-ERCC1 enhances 
cisplatin efficacy in cancer cells. DNA Repair (Amst). 2010; 
9:745–53. https://doi.org/10.1016/j.dnarep.2010.03.010.
23. Song L, Ritchie AM, McNeil EM, Li W, Melton DW. 
Identification of DNA repair gene Ercc1 as a novel target in 
melanoma. Pigment Cell Melanoma Res. 2011; 24:966–71. 
https://doi.org/10.1111/j.1755-148X.2011.00882.x.
24. Barakat KH, Torin Huzil J, Luchko T, Jordheim L, Dumontet 
C, Tuszynski J. Characterization of an inhibitory dynamic 
pharmacophore for the ERCC1-XPA interaction using 
a combined molecular dynamics and virtual screening 
approach. J Mol Graph Model. 2009; 28:113–30. https://doi.
org/10.1016/j.jmgm.2009.04.009.
25. Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart 
D, Dumontet C, Tuszynski JA. Virtual screening and 
biological evaluation of inhibitors targeting the XPA-
ERCC1 interaction. PLoS One. 2012; 7:e51329. https://doi.
org/10.1371/journal.pone.0051329.
26. Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, 
Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro 
R, Wishart DS, Cohen R, Tuszynski J, Dumontet C. 
Small molecule inhibitors of ERCC1-XPF protein-protein 
interaction synergize alkylating agents in cancer cells. 
Mol Pharmacol. 2013; 84:12–24. https://doi.org/10.1124/
mol.112.082347.
Oncotarget19www.impactjournals.com/oncotarget
27. McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, 
Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, 
Wear MA, Walkinshaw MD, Saxty B, et al. Inhibition of the 
ERCC1-XPF structure-specific endonuclease to overcome 
cancer chemoresistance. DNA Repair (Amst). 2015; 31:19–
28. https://doi.org/10.1016/j.dnarep.2015.04.002.
28. Chapman TM, Wallace C, Gillen KJ, Bakrania P, Khurana 
P, Coombs PJ, Fox S, Bureau EA, Brownlees J, Melton DW, 
Saxty B. N-Hydroxyimides and hydroxypyrimidinones as 
inhibitors of the DNA repair complex ERCC1-XPF. Bioorg 
Med Chem Lett. 2015; 25:4104–08. https://doi.org/10.1016/j.
bmcl.2015.08.024.
29. Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania 
P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau 
EA, Brownlees J, Melton DW, Saxty B. Catechols and 
3-hydroxypyridones as inhibitors of the DNA repair complex 
ERCC1-XPF. Bioorg Med Chem Lett. 2015; 25:4097–103. 
https://doi.org/10.1016/j.bmcl.2015.08.031.
30. Li W, Melton DW. Cisplatin regulates the MAPK kinase 
pathway to induce increased expression of DNA repair gene 
ERCC1 and increase melanoma chemoresistance. Oncogene. 
2012; 31:2412–22. https://doi.org/10.1038/onc.2011.426.
31. Jackson SP, Durocher D. Regulation of DNA damage 
responses by ubiquitin and SUMO. Mol Cell. 2013; 49:795–
807. https://doi.org/10.1016/j.molcel.2013.01.017.
32. Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of 
protein degradation and processing. Biochemistry (Mosc). 2009; 
74:1411–42. https://doi.org/10.1134/S000629790913001X.
33. Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: 
cell biological roles of proteasome activators and inhibitors. 
Trends Cell Biol. 2005; 15:27–33. https://doi.org/10.1016/j.
tcb.2004.11.003.
34. Bianchi K, Meier P. A tangled web of ubiquitin chains: 
breaking news in TNF-R1 signaling. Mol Cell. 2009; 36:736–
42. https://doi.org/10.1016/j.molcel.2009.11.029.
35. Reggiori F, Klionsky DJ. Autophagosomes: biogenesis from 
scratch? Curr Opin Cell Biol. 2005; 17:415–22. https://doi.
org/10.1016/j.ceb.2005.06.007.
36. Behrends C, Harper JW. Constructing and decoding 
unconventional ubiquitin chains. Nat Struct Mol Biol. 2011; 
18:520–28. https://doi.org/10.1038/nsmb.2066.
37. Wang X, Herr RA, Chua WJ, Lybarger L, Wiertz EJ, Hansen 
TH. Ubiquitination of serine, threonine, or lysine residues on 
the cytoplasmic tail can induce ERAD of MHC-I by viral 
E3 ligase mK3. J Cell Biol. 2007; 177:613–24. https://doi.
org/10.1083/jcb.200611063.
38. Cadwell K, Coscoy L. Ubiquitination on nonlysine residues 
by a viral E3 ubiquitin ligase. Science. 2005; 309:127–30. 
https://doi.org/10.1126/science.1110340.
39. Ravid T, Hochstrasser M. Autoregulation of an E2 enzyme 
by ubiquitin-chain assembly on its catalytic residue. Nat Cell 
Biol. 2007; 9:422–27. https://doi.org/10.1038/ncb1558.
40. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev 
Biochem. 1998; 67:425–79. https://doi.org/10.1146/annurev.
biochem.67.1.425.
41. Nishino T, Komori K, Ishino Y, Morikawa K. X-ray and 
biochemical anatomy of an archaeal XPF/Rad1/Mus81 
family nuclease: similarity between its endonuclease domain 
and restriction enzymes. Structure. 2003; 11:445–57. https://
doi.org/10.1016/S0969-2126(03)00046-7.
42. Sijbers AM, van der Spek PJ, Odijk H, van den Berg J, van 
Duin M, Westerveld A, Jaspers NG, Bootsma D, Hoeijmakers 
JH. Mutational analysis of the human nucleotide excision 
repair gene ERCC1. Nucleic Acids Res. 1996; 24:3370–80. 
https://doi.org/10.1093/nar/24.17.3370.
43. Gentile F, Tuszynski JA, Barakat KH. New design of 
nucleotide excision repair (NER) inhibitors for combination 
cancer therapy. J Mol Graph Model. 2016; 65:71–82. https://
doi.org/10.1016/j.jmgm.2016.02.010.
44. Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, 
Floyd AM, Chalfin EM, Bepler G, Patrick SM. Identification 
of small molecule inhibitors of ERCC1-XPF that inhibit 
DNA repair and potentiate cisplatin efficacy in cancer cells. 
Oncotarget. 2016; 7:75104–17. https://doi.org/10.18632/
oncotarget.12072.
45. Perez-Oliva AB, Lachaud C, Szyniarowski P, Muñoz 
I, Macartney T, Hickson I, Rouse J, Alessi DR. USP45 
deubiquitylase controls ERCC1-XPF endonuclease-mediated 
DNA damage responses. EMBO J. 2015; 34:326–43. https://
doi.org/10.15252/embj.201489184.
46. Komander D, Rape M. The ubiquitin code. Annu Rev 
Biochem. 2012; 81:203–29. https://doi.org/10.1146/annurev-
biochem-060310-170328.
47. Glickman MH, Maytal V. Regulating the 26S proteasome. 
Curr Top Microbiol Immunol. 2002; 268:43–72. https://doi.
org/10.1007/978-3-642-59414-4_3.
48. Fosgerau K, Hoffmann T. Peptide therapeutics: current status 
and future directions. Drug Discov Today. 2015; 20:122–28. 
https://doi.org/10.1016/j.drudis.2014.10.003.
49. Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, 
Dumontet C. Expression of domains for protein-protein 
interaction of nucleotide excision repair proteins modifies 
cancer cell sensitivity to platinum derivatives and genomic 
stability. Clin Exp Pharmacol Physiol. 2014; 41:817–24. 
https://doi.org/10.1111/1440-1681.12282.
50. Huschtscha LI, Holliday R. Limited and unlimited growth 
of SV40-transformed cells from human diploid MRC-5 
fibroblasts. J Cell Sci. 1983; 63:77–99.
51. Thoms HC, Loveridge CJ, Simpson J, Clipson A, Reinhardt 
K, Dunlop MG, Stark LA. Nucleolar targeting of RelA(p65) 
is regulated by COMMD1-dependent ubiquitination. Cancer 
Res. 2010; 70:139–49. https://doi.org/10.1158/0008-5472.
CAN-09-1397.
52. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of 
proteins from polyacrylamide gels to nitrocellulose sheets: 
procedure and some applications. Proc Natl Acad Sci USA. 
1979; 76:4350–54. https://doi.org/10.1073/pnas.76.9.4350.
53. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, 
Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 
New colorimetric cytotoxicity assay for anticancer-drug 
screening. J Natl Cancer Inst. 1990; 82:1107–12. https://doi.
org/10.1093/jnci/82.13.1107.
